Inspire Medical Systems (NYSE:INSP) Upgraded at Barclays

Barclays upgraded shares of Inspire Medical Systems (NYSE:INSP) to a strong sell rating in a research report report published on Tuesday morning,Zacks reports.

INSP has been the topic of several other reports. Zacks Research lowered shares of Inspire Medical Systems from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 22nd. Truist Financial restated a “hold” rating and issued a $62.00 price objective (up from $54.00) on shares of Inspire Medical Systems in a report on Tuesday, August 4th. Royal Bank Of Canada lifted their target price on Inspire Medical Systems from $60.00 to $75.00 and gave the company a “sector perform” rating in a research report on Thursday, October 1st. Robert W. Baird upped their target price on Inspire Medical Systems from $54.00 to $59.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. Finally, Weiss Ratings raised Inspire Medical Systems from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, twelve have given a Hold rating and four have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $67.29.

Inspire Medical Systems Stock Down 1.4%

NYSE:INSP opened at $66.50 on Tuesday. The company has a market cap of $1.92 billion, a P/E ratio of 14.39, a price-to-earnings-growth ratio of 5.10 and a beta of 0.73. Inspire Medical Systems has a twelve month low of $38.91 and a twelve month high of $147.03. The business has a 50 day moving average price of $64.86 and a two-hundred day moving average price of $54.06.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings data on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.38. The company had revenue of $200.58 million for the quarter, compared to the consensus estimate of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The firm’s revenue was down 7.6% compared to the same quarter last year. During the same period last year, the company earned $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, analysts anticipate that Inspire Medical Systems will post 1.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Inspire Medical Systems news, insider Jason Kelly sold 963 shares of the company’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the transaction, the insider directly owned 18,985 shares in the company, valued at $1,130,556.75. The trade was a 4.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 2.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. WINTON GROUP Ltd grew its position in shares of Inspire Medical Systems by 790.8% in the second quarter. WINTON GROUP Ltd now owns 37,412 shares of the company’s stock valued at $1,669,000 after purchasing an additional 33,212 shares during the last quarter. Legal & General Group Plc bought a new stake in Inspire Medical Systems in the 2nd quarter valued at $2,732,000. Alberta Investment Management Corp acquired a new position in Inspire Medical Systems in the 2nd quarter valued at $5,483,000. GSA Capital Partners LLP acquired a new position in Inspire Medical Systems in the 2nd quarter valued at $820,000. Finally, Empowered Funds LLC bought a new position in Inspire Medical Systems during the 2nd quarter worth $2,260,000. Institutional investors and hedge funds own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company focused on developing and commercializing treatments for obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly becomes blocked during sleep. The company’s primary product is the Inspire therapy system, an implantable device designed for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefits from continuous positive airway pressure (CPAP) therapy.

The Inspire system uses an implantable pulse generator, a stimulation lead and a sensing lead.